According to filings with the U.S. Securities and Exchange Commission, Headlands Research is raising $9,999,998.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Kyle Burtnett played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Headlands Research
Headlands Research is a leading globally integrated site organization with a mission of profoundly impacting the clinical trials process. Headlands Research is comprised of the highest quality dedicated and embedded research centers across North America. Our investigators and sites have completed 5,000+ Phase I-IV trials to date in various TA areas including but not limited to Allergy, Cardiovascular, Dermatology, Emergency Medicine, Endocrinology, Family Medicine, Family Practice, Gastroenterology, Immunology, Infectious Disease Prophylaxis and Treatment, Internal Medicine, Nephrology, Neurology. Obstetrics and Gynecology (OB/GYN), Oncology, Ophthalmology, Orthopaedics, Otolaryngology (ENT), Pediatrics, Physical Medicine and Rehabilitation, Plastic Surgery, Preventive Medicine, Psychiatry, Urology and Vaccine.

To learn more about Headlands Research, visit http://www.headlandsresearch.com/

Contact:
Kyle Burtnett, Chief Executive Officer
727-543-4604

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.